M.E. Information

 
 
sticker_sheet.jpg 
 
 
  • What is M.E.?

    The most frequently asked questions form this resource, which doubles as a useful information sheet to download.

    Myalgic "my-AL-jik" means muscle pain.
    Encephalomyelitis "en-SEF-uh-lo-MY-uh-LY-tis" means inflammation of the brain and spinal cord.


  • A Short History of M.E.

    An insight into the history of this debilitating condition and the efforts to change its name (approx. 2,000 words).

  • The Symptoms of M.E.

    This is the longest and most vital article on M.E. Support which can also be downloaded. It covers the cardinal symptoms, secondary features and characterised symptoms. This article includes information about NICE guidelines and the latest clinical criteria.

  • M.E. Diagnosis, Treatment & Prognosis

    This article summarises the diagnosis, treatment and prognosis of M.E., including information about NHS Specialist Services.

  • A Self-Help Guide to Managing M.E.

    A clear and enlightening self-help guide to managing M.E. and other debilitating conditions.

  • M.E./CFS Research

    A summary of past and present studies along with useful links and a research news feed. This article will be updated in due course.

  • M.E. Organisations

    An extensive resource listing worldwide organisations, including regional groups in the United Kingdom.

  • M.E. Disability Scale

    This simple yet effective resource is available to download and can help you follow your progress or provide information for medical assessments.

  • Money Matters

    This resource consists of links and information about finance and welfare, along with other useful services in the UK.
 
 
 
 
contactMESUK2
 
 
 
 

Back to Top ↑

 

News

Page 1 of 2  > >>

6 Jul 2019
M.E. Organisations
30 Jun 2019
Pets & Chronic Illness
29 Jun 2019
Forward-ME
21 Jun 2019
New Article Published
4 Jun 2019
Keyrings Back In Stock
30 Apr 2019
Biomarker for 'CFS' identified
13 Apr 2019
NIH Conference Videos
13 Apr 2019
CFS/ME National Services Survey
6 Apr 2019
Phase 3 Rituximab Trial
1 Apr 2019
Anniversary Statement